Marshall Wace, LLP Pacira Bio Sciences, Inc. Call Options Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PCRX
# of Institutions
264Shares Held
50.6MCall Options Held
429KPut Options Held
391K-
Black Rock Inc. New York, NY8.01MShares$159 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.3MShares$105 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA4.96MShares$98.6 Million0.18% of portfolio
-
State Street Corp Boston, MA2.01MShares$40 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.98MShares$39.3 Million0.05% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $911M
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...